Tuesday, September 26, 2017 3:34:24 AM
Hard to be hopeful, though. In the Sept. 8 press release, Eves cited a vague "later this year" timeline for the plant design. But he did it with typical weasel language, firmly buttressed by a forward-looking statements disclaimer.
In the same PR, with the same weaselly tee-up, backed up by the same forward-looking statements disclaimer, Neary at least provided a more specific four-week timeline for the alleged final round of testing. Based on that, we are midway to its Oct. 10 completion.
Place your bets.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM